Moreover, measurement of serum Fuc-Hpt concentrations was superior compared to measurement of the M30 antigen in distinguishing NASH patients from non-NASH patients and predicting both the presence of ballooning hepatocytes and fibrosis severity in NAFLD patients. The gene discussed is MRS2; the disease is metabolic dysfunction-associated steatotic liver disease.